PathAI vs Qure.ai

Qure.ai has a disclosed valuation of $270M, while PathAI's valuation is not publicly available, making a direct size comparison difficult. Qure.ai employs 250 people.

PathAI has raised more in total funding at $255M, compared to Qure.ai's $157M — a gap of $98M. Combined, the two companies have completed 8 known funding rounds.

Qure.ai holds the higher Awaira Score at 70/100, compared to PathAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

PathAI was founded by Andy Beck in 2016. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.

PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.

Both PathAI and Qure.ai were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

PathAI has approximately 300 employees, while Qure.ai has approximately 250. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, PathAI and Qure.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.